Company Overview - Ascentage Pharma was founded in 2009 and has established itself as a global commercial stage company focused on hematology and oncology [3] - The company has two novel commercial products targeting BCR-ABL and Bcl-2, highlighting its innovative approach in the oncology sector [3] - Ascentage is dual listed on NASDAQ and the Hong Kong Stock Exchange, indicating its significant market presence [3] Financial Position - As of the last financial report, Ascentage holds $420 million in cash, which is expected to support its current research and development plans [3]